Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype.

نویسندگان

  • Sunil R Lakhani
  • Jorge S Reis-Filho
  • Laura Fulford
  • Frederique Penault-Llorca
  • Marc van der Vijver
  • Suzanne Parry
  • Timothy Bishop
  • Javier Benitez
  • Carmen Rivas
  • Yves-Jean Bignon
  • Jenny Chang-Claude
  • Ute Hamann
  • Cees J Cornelisse
  • Peter Devilee
  • Matthias W Beckmann
  • Carolin Nestle-Krämling
  • Peter A Daly
  • Neva Haites
  • Jenny Varley
  • Fiona Lalloo
  • Gareth Evans
  • Christine Maugard
  • Hanne Meijers-Heijboer
  • Jan G M Klijn
  • Edith Olah
  • Barry A Gusterson
  • Silvana Pilotti
  • Paolo Radice
  • Siegfried Scherneck
  • Hagay Sobol
  • Jocelyne Jacquemier
  • Teresa Wagner
  • Julian Peto
  • Michael R Stratton
  • Lesley McGuffog
  • Douglas F Easton
چکیده

PURPOSE To investigate the proportion of breast cancers arising in patients with germ line BRCA1 and BRCA2 mutations expressing basal markers and developing predictive tests for identification of high-risk patients. EXPERIMENTAL DESIGN Histopathologic material from 182 tumors in BRCA1 mutation carriers, 63 BRCA2 carriers, and 109 controls, collected as part of the international Breast Cancer Linkage Consortium were immunohistochemically stained for CK14, CK5/6, CK17, epidermal growth factor receptor (EGFR), and osteonectin. RESULTS All five basal markers were commoner in BRCA1 tumors than in control tumors (CK14: 61% versus 12%; CK5/6: 58% versus 7%; CK17: 53% versus 10%; osteonectin: 43% versus 19%; EGFR: 67% versus 21%; P < 0.0001 in each case). In a multivariate analysis, CK14, CK5/6, and estrogen receptor (ER) remained significant predictors of BRCA1 carrier status. In contrast, the frequency of basal markers in BRCA2 tumors did not differ significant from controls. CONCLUSION The use of cytokeratin staining in combination with ER and morphology provides a more accurate predictor of BRCA1 mutation status than previously available, that may be useful in selecting patients for BRCA1 mutation testing. The high percentage of BRCA1 cases positive for EGFR suggests that specific anti-tyrosine kinase therapy may be of potential benefit in these patients.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Relation between Estrogen and Progesterone Receptor Status with p53, Ki67 and Her-2 Markers in Patients with Breast Cancer

Background: Breast cancer is the most common cancer in women, containing approximately one third of all illnesses in women. Assessment of molecular markers is valuable in predicting the outcome of disease and decision making for optimal treatment. The purpose of this study was to determine the relationship between estrogen and progesterone receptors with Her-2, Ki67, P53, and clinicopathologica...

متن کامل

PREDICTION OF ESTROGEN RECEPTOR STATUS OF INVASIVE DUCTAL CARCINOMA OF BREAST BY HISTOLOGIC GRADE

In human breast cancer, estrogen receptor (ER) status of the tumor has prognostic and therapeutic significance. However, facilities to study ER are not widely available to us. We postulated that if there is a correlation between histologic grade and ER status of invasive ductal carcinoma (IDC), it may help predict the ER status of the tumor. Of 8 4 cases of breast carcinoma referred to the ...

متن کامل

Correlation of Hormone Receptor Expression with Histologic Parameters in Benign and Malignant Breast Tumors

Background and Objective: Breast cancer is the commonest cancer of Indian women. Estrogen and Progesterone expression is seen in benign breast lesions and in breast carcinoma associated with good prognostic parameters and it correlates well with response to hormone therapy. Although a lot of studies have been conducted in the past on hormone receptor expression in breast cancer and few have cor...

متن کامل

Bioinformatics-Based Prediction of FUT8 as a Therapeutic Target in Estrogen Receptor-Positive Breast Cancer

Abstract Introduction: Estrogen receptor-positive (ER-positive) breast cancer is a subgroup of breast tumors that is more likely to respond to hormone therapy. ER-positive and ER- negative breast cancers tend to show different patterns of metastasis because of different signaling cascade and genes that are activated by estrogen response. Genetic factors can contribute to high rates of metastas...

متن کامل

Bioinformatics-Based Prediction of FUT8 as a Therapeutic Target in Estrogen Receptor-Positive Breast Cancer

Abstract Introduction: Estrogen receptor-positive (ER-positive) breast cancer is a subgroup of breast tumors that is more likely to respond to hormone therapy. ER-positive and ER- negative breast cancers tend to show different patterns of metastasis because of different signaling cascade and genes that are activated by estrogen response. Genetic factors can contribute to high rates of metastas...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • Clinical cancer research : an official journal of the American Association for Cancer Research

دوره 11 14  شماره 

صفحات  -

تاریخ انتشار 2005